{"689424":{"#nid":"689424","#data":{"type":"news","title":"Georgia Tech-led Research Team to Develop SHIELD Against Deadly Biological Threats","body":[{"value":"\u003Cp\u003EThe United States continues to face deadly infectious disease outbreaks, from emerging viruses to antibiotic-resistant bacteria, underscoring the nation\u2019s need for rapid, effective response systems. These threats extend beyond public health, disrupting daily life, straining health care systems, and impacting military readiness.\u003C\/p\u003E\u003Cp\u003EA team of researchers led by \u003Ca href=\u0022https:\/\/me.gatech.edu\/faculty\/singh\u0022\u003E\u003Cstrong\u003EAnkur Singh\u003C\/strong\u003E\u003C\/a\u003E, the Carl Ring Family Professor in the \u003Ca href=\u0022https:\/\/www.me.gatech.edu\/\u0022\u003E\u003Cstrong\u003EGeorge W. Woodruff School of Mechanical Engineering\u003C\/strong\u003E\u003C\/a\u003E and professor in\u003Cstrong\u003E\u0026nbsp;\u003C\/strong\u003Ethe \u003Ca href=\u0022https:\/\/bme.gatech.edu\/bme\/\u0022\u003E\u003Cstrong\u003EWallace H. Coulter Department of Biomedical Engineering\u003C\/strong\u003E\u003C\/a\u003E at Georgia Tech and Emory\u0026nbsp;University, has been awarded up to $6 million from the Defense Threat Reduction Agency (DTRA) of the U.S. Department of Defense to accelerate the development of medical countermeasures (MCMs) against deadly biological threats that endanger public health, national security, and warfighters.\u003C\/p\u003E\u003Cp\u003EDTRA\u2019s mission is to provide solutions that enable the Department of Defense, the U.S. government, and international partners to deter strategic threats. A key priority is advancing new or improved MCMs that can be deployed before or after exposure to biological or chemical agents.\u003C\/p\u003E\u003Cp\u003ESingh\u2019s multi-year project, Systematic Human Immune Engineering for Lethal Disease (SHIELD) Countermeasures, aims to create a threat-agnostic platform that transforms how respiratory pathogens and toxins are studied. The platform is designed to speed up the discovery, development, and production of immune-based countermeasures.\u003C\/p\u003E\u003Cp\u003ESingh leads a collaborative team that includes Cornell University\u2019s Matthew DeLisa and Stanford University\u2019s Michael Jewett. Together, they will integrate immune-engineering technologies with advanced cell-free protein synthesis platforms to discover and manufacture protein-based MCMs. Cell-free protein synthesis is a laboratory technique that efficiently produces proteins without relying on living cells, which can be unpredictable and technically demanding when it comes to expressing complex or toxic proteins and scaling production quickly. The team expects the SHIELD Countermeasures platform to reduce the time and cost of MCM development by more than tenfold.\u003C\/p\u003E\u003Cp\u003E\u201cThe foundational science and cutting-edge tools we develop will ignite future discoveries, ensuring a robust pipeline of advanced protein-based MCMs for chemical and biological defense,\u201d said Singh, who also directs the \u003Ca href=\u0022https:\/\/immunoengineering.gatech.edu\/\u0022\u003E\u003Cstrong\u003ECenter for Immunoengineering at Georgia Tech\u003C\/strong\u003E\u003C\/a\u003E. \u201cThis will significantly enhance national security and equip our warfighters with next-generation biodefense capabilities.\u0022\u003C\/p\u003E\u003Cp\u003ETraditional animal models often fail to accurately replicate human immune responses, and standard tissue cultures lack the complexity required to study how immune cells interact with pathogens. In contrast, human immune organoids and immune-competent devices \u2014 built from human cells \u2014 are emerging as groundbreaking research tools. These systems recreate key immune features, such as lymph nodes and mucosal environments, within three-dimensional or microengineered platforms.\u003C\/p\u003E\u003Cp\u003E\u201cMany organoid and engineering devices, often called organ-on-chip platforms, lack immune integration,\u201d Singh said. \u201cBecause immunity sits at the center of human health, these limitations have broad consequences. Immune-competent organ-on-chip platforms extend this concept by combining human cells with microfluidic engineering that simulates blood flow, tissue barriers, and chemical gradients.\u201d\u003C\/p\u003E\u003Cp\u003ESingh has previously published studies on a synthetic \u003Ca href=\u0022https:\/\/www.nature.com\/articles\/s41563-024-02037-1\u0022\u003E\u003Cstrong\u003Ehuman immune chip\u003C\/strong\u003E\u003C\/a\u003E and an \u003Ca href=\u0022https:\/\/www.nature.com\/articles\/s41551-025-01491-9\u0022\u003E\u003Cstrong\u003Eimmunocompetent lung on a chip\u003C\/strong\u003E\u003C\/a\u003E, and has also teamed up with DeLisa previously to use synthetic immune organoids for \u003Ca href=\u0022https:\/\/pubs.acs.org\/doi\/10.1021\/acscentsci.2c01473\u0022\u003E\u003Cstrong\u003Eimmuno-profiling antibacterial MCMs\u003C\/strong\u003E\u003C\/a\u003E.\u003C\/p\u003E\u003Cp\u003E\u201cIt\u2019s about being able to test far larger numbers of candidate protein-based MCMs in a single experiment\u2014and to do it much faster,\u201d DeLisa said. \u201cCell-free systems allow us to produce MCMs at unprecedented speed and scale, but traditional evaluation methods can\u2019t keep up with those numbers. By combining cell-free MCM production with immune organoid technology, we can assess the potency of dozens or even hundreds of candidates at a time and characterize the resulting immune responses within just a few days.\u201d\u003C\/p\u003E\u003Cp\u003EBy integrating immune cells with tissues such as lung, gut, skin, or vascular systems, these devices allow scientists to observe immune responses in real time, including cell migration, inflammation, and interactions with pathogens or therapeutics. As biological threats evolve, the development and deployment of immune-competent platforms will be critical for rapid, effective countermeasures.\u003C\/p\u003E\u003Cp\u003EDTRA\u2019s investment in Singh\u2019s work highlights the urgent national priority of strengthening U.S. biodefense capabilities. The SHIELD Countermeasures platform and its cutting-edge technologies promise to transform the nation\u2019s response to biological threats and help safeguard communities from biological and chemical attacks.\u003C\/p\u003E","summary":"","format":"limited_html"}],"field_subtitle":"","field_summary":[{"value":"\u003Cdiv\u003ELed by Ankur Singh, the multi-institutional SHIELD (Systematic Human Immune Engineering for Lethal Disease) project aims to transform how scientists study and respond to dangerous respiratory pathogens and toxins. The effort brings together researchers from Georgia Tech, Cornell, and Stanford to enable faster and more cost-effective development of protein-based medical countermeasures. The team expects the platform to reduce the time and cost of developing these defenses by more than tenfold, strengthening the nation\u2019s preparedness against biological threats.\u003C\/div\u003E","format":"limited_html"}],"field_summary_sentence":[{"value":"A Georgia Tech-led research team has received up to $6 million to develop SHIELD, a new platform designed to rapidly create immune-based countermeasures against a wide range of deadly biological threats."}],"uid":"36479","created_gmt":"2026-04-02 19:06:48","changed_gmt":"2026-04-02 19:17:40","author":"abowman41","boilerplate_text":"","field_publication":"","field_article_url":"","location":"Atlanta, GA","dateline":{"date":"2026-04-02T00:00:00-04:00","iso_date":"2026-04-02T00:00:00-04:00","tz":"America\/New_York"},"extras":[],"hg_media":{"679841":{"id":"679841","type":"image","title":"DTRA-2.jpg","body":null,"created":"1775156814","gmt_created":"2026-04-02 19:06:54","changed":"1775156814","gmt_changed":"2026-04-02 19:06:54","alt":"Ankur Singh, a man in a gray suit jacket with a dark pink button-up shirt stands in front of a work bench in a lab.","file":{"fid":"264047","name":"DTRA-2.jpg","image_path":"\/sites\/default\/files\/2026\/04\/02\/DTRA-2.jpg","image_full_path":"http:\/\/hg.gatech.edu\/\/sites\/default\/files\/2026\/04\/02\/DTRA-2.jpg","mime":"image\/jpeg","size":1541575,"path_740":"http:\/\/hg.gatech.edu\/sites\/default\/files\/styles\/740xx_scale\/public\/2026\/04\/02\/DTRA-2.jpg?itok=UsJZzTJB"}}},"media_ids":["679841"],"groups":[{"id":"1292","name":"Parker H. Petit Institute for Bioengineering and Bioscience (IBB)"},{"id":"1188","name":"Research Horizons"}],"categories":[{"id":"138","name":"Biotechnology, Health, Bioengineering, Genetics"},{"id":"145","name":"Engineering"}],"keywords":[{"id":"188776","name":"go-research"},{"id":"187423","name":"go-bio"},{"id":"190256","name":"G.W. Woodruff School of Mechanical Engineering"},{"id":"187915","name":"go-researchnews"}],"core_research_areas":[{"id":"39441","name":"Bioengineering and Bioscience"}],"news_room_topics":[],"event_categories":[],"invited_audience":[],"affiliations":[],"classification":[],"areas_of_expertise":[],"news_and_recent_appearances":[],"phone":[],"contact":[{"value":"\u003Cp\u003ETracie Troha | Communications Officer, Mechanical Engineering\u003C\/p\u003E","format":"limited_html"}],"email":[],"slides":[],"orientation":[],"userdata":""}}}